NCT06850090 2025-06-25
Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial
Shandong Cancer Hospital and Institute
Phase 3 Not yet recruiting
Shandong Cancer Hospital and Institute
Biotech Pharmaceutical Co., Ltd.